Table 2.
Treatment-related hematological and non-hematological toxicities in patients with diffuse large B cell lymphoma
| No. (%) of cycles | No. (%) of patients | |
|---|---|---|
|
Hematological toxicities* |
||
| anemia (grade 3 or 4) |
65/371 (18.0) |
36/63 (57.0) |
| thrombocytopenia (grade 3 or 4) |
63/371 (17.0) |
35/63 (56.0) |
| neutropenia (grade 4) |
152/371 (41.0) |
58/63 (92.0) |
| febrile neutropenia |
66/371 (18.0) |
40/63 (63.0) |
|
Non-hematological toxicities |
||
| venous thrombosis | - | 9/75 (12.0) |
| catheter-related |
- |
7/75 (9.0) |
| cerebrovascular infarction |
- |
1/75 (1.0) |
| polyneuropathy gr. ≥2 |
- |
11/75 (15.0) |
| gastrointestinal hemorrhage |
- |
3/75 (4.0) |
| hepatitis B reactivation |
- |
1/75 (1.0) |
| hemorrhagic cystitis |
- |
1/75 (1.0) |
| Treatment discontinuation |
- |
9/75 (12.0) |
| Deaths during treatment | - | 9/75 (12.0) |
*Data available for 63 patients who received a total of 371 cycles.